CryoPort, Inc. (NASDAQ:CYRX) Receives $12.83 Average Price Target from Analysts

by · The Markets Daily

Shares of CryoPort, Inc. (NASDAQ:CYRX – Get Free Report) have received an average rating of “Moderate Buy” from the eleven analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $12.8333.

CYRX has been the subject of several analyst reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of CryoPort in a research note on Monday. Needham & Company LLC upped their price objective on shares of CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. BTIG Research raised their target price on shares of CryoPort from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. Finally, UBS Group boosted their target price on shares of CryoPort from $11.00 to $12.50 and gave the company a “buy” rating in a report on Wednesday, November 5th.

Check Out Our Latest Stock Analysis on CYRX

Insider Activity at CryoPort

In other news, Director Ramkumar Mandalam sold 11,570 shares of the company’s stock in a transaction on Wednesday, December 10th. The stock was sold at an average price of $9.99, for a total transaction of $115,584.30. Following the completion of the sale, the director directly owned 80,758 shares in the company, valued at $806,772.42. This represents a 12.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 10.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CryoPort

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC lifted its stake in shares of CryoPort by 299.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company’s stock valued at $27,000 after purchasing an additional 2,729 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in CryoPort by 300.1% during the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock valued at $44,000 after buying an additional 4,375 shares in the last quarter. Whittier Trust Co. of Nevada Inc. purchased a new stake in CryoPort during the third quarter worth approximately $53,000. ProShare Advisors LLC acquired a new stake in shares of CryoPort in the second quarter worth $75,000. Finally, AlphaQuest LLC acquired a new stake in shares of CryoPort in the third quarter worth $79,000. 92.90% of the stock is currently owned by institutional investors and hedge funds.

CryoPort Stock Performance

NASDAQ:CYRX opened at $9.32 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 15.77 and a quick ratio of 15.01. The firm has a market cap of $466.65 million, a PE ratio of 7.97 and a beta of 1.51. The firm has a 50 day simple moving average of $9.39 and a 200-day simple moving average of $8.57. CryoPort has a 1-year low of $4.58 and a 1-year high of $11.44.

CryoPort (NASDAQ:CYRX – Get Free Report) last released its earnings results on Tuesday, November 4th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05. The firm had revenue of $44.23 million during the quarter, compared to analysts’ expectations of $41.22 million. CryoPort had a net margin of 35.57% and a negative return on equity of 11.07%. On average, equities analysts expect that CryoPort will post -0.99 EPS for the current year.

CryoPort Company Profile

(Get Free Report)

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

See Also